预约演示
更新于：2025-09-15
Leuprolide Acetate
醋酸亮丙瑞林
更新于：2025-09-15
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1985-04-09), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C59H84N16O12.C2H4O2 |
InChIKeyRGLRXNKKBLIBQS-XNHQSDQCSA-N |
CAS号74381-53-6 |
Sequence Code 20294387
关联
321
项与 醋酸亮丙瑞林 相关的临床试验NCT07158021
Phase 2 Randomized Trial to Examine Ovarian Function Suppression for Breast Cancer (OFS)
NCT06654336
Phase II Randomized Trial of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC).
NCT07027124
Neoadjuvant ADT and Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in NCCN High-risk and Molecularly Stratified Prostate Cancer Patients
100 项与 醋酸亮丙瑞林 相关的临床结果
登录后查看更多信息
100 项与 醋酸亮丙瑞林 相关的转化医学
登录后查看更多信息
100 项与 醋酸亮丙瑞林 相关的专利（医药）
登录后查看更多信息
3,592
项与 醋酸亮丙瑞林 相关的文献（医药）2025-10-01The French Journal of Urology
Relugolix in prostate cancer therapy: Clinical evidence and practical considerations
Article
作者: Peyrottes, Arthur ; Barret, Eric ; Dariane, Charles ; Ploussard, Guillaume ; Sargos, Paul ; Olivier, Jonathan ; Brureau, Laurent ; Baboudjian, Michael ; Supiot, Stephane ; Mathieu, Romain
INTRODUCTION:
Androgen deprivation therapy (ADT) remains a cornerstone of treatment for both localized and metastatic prostate cancer (PC). Relugolix, an oral gonadotrophin-releasing hormone antagonist, provides a new option for achieving rapid testosterone suppression using an oral formulation.
MATERIALS AND METHODS:
A comprehensive literature search was conducted in PubMed by combining the search terms "relugolix", "TAK-385", "MVT-601", "prostate cancer", and "prostatic neoplasms" and focusing on prospective and retrospective studies published in English.
RESULTS:
The HERO pivotal phase III trial demonstrated sustained testosterone suppression in 96.7% of patients with PC treated with relugolix versus 88.8% with leuprolide through to 48weeks (P<0.001). Relugolix achieved faster testosterone suppression and recovery post-treatment and a 54% lower risk of major adverse cardiovascular events compared with leuprolide. Data from HERO and phase II studies also support its use in combination with radiotherapy or other systemic therapies. Real-world studies performed to date have confirmed the effectiveness of relugolix, with more than 98% patients achieving castrate testosterone levels. Adherence to relugolix was generally high, and its safety profile aligned with clinical trial data. Practical considerations include, among others, treatment combination and drug-drug interactions, patient choice, and oncological outcomes.
CONCLUSIONS:
Clinical trials and real-world evidence support relugolix as a convenient and effective ADT option for PC. It offers rapid and sustained testosterone suppression, potential cardiovascular benefits, and an alternative to injectable therapies. Long-term adherence, the use of combination treatments and related drug-drug interactions require further investigation.
2025-09-01EClinicalMedicine
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis
Article
作者: Freedland, Stephen J ; Reisman, Arlene L ; Rannikko, Antti ; Nasr, Anchen F ; Ivanova, Jasmina I ; Ramirez-Backhaus, Miguel ; De Giorgi, Ugo ; Saad, Fred ; Shore, Neal D ; Kral, Pavol ; Ganguli, Arijit
Background:
Enzalutamide was approved for high-risk biochemically recurrent (hrBCR) prostate cancer based on the EMBARK trial (NCT02319837; 17 December 2014-31 January 2023). In EMBARK, treatment was suspended at week 37 if prostate-specific antigen (PSA) was <0.2 ng/mL and reinstated if PSA rose to ≥2.0 ng/mL with radical prostatectomy or ≥5.0 ng/mL without. This post hoc analysis assessed the impact of treatment suspension on health-related quality of life (HRQoL) to address overtreatment concerns.
Methods:
Longitudinal change in HRQoL from treatment suspension at week 37 to subsequent assessments until week 109 was analyzed with mixed models for repeated measures (MMRM) and descriptively among these patients. Separate models were used to assess four patient-reported outcome (PRO) instruments-Brief Pain Inventory - short form, Functional Assessment of Cancer Therapy - Prostate, QoL Questionnaire - Prostate 25, and European QoL 5-Dimensions 5-Levels health questionnaire-with predefined clinically meaningful thresholds. Intention-to-treat analysis was used.
Findings:
Treatment was suspended in 90% (321/355), 86% (304/355), and 67% (240/358) of participants treated with enzalutamide + leuprolide, enzalutamide monotherapy, and leuprolide alone, respectively. MMRM showed no meaningful change in any treatment arm after treatment suspension across all assessed PRO measures, except hormonal treatment-related symptoms, for which clinically meaningful improvement was observed after treatment suspension at week 61 for enzalutamide monotherapy, week 73 for leuprolide alone, and week 85 for enzalutamide + leuprolide. The descriptive analysis showed similar findings.
Interpretation:
Enzalutamide ± leuprolide in patients with hrBCR improves metastasis-free survival versus leuprolide alone with no clinically meaningful changes in the measured HRQoL domains during treatment or after treatment suspension, with gradual improvement in hormonal treatment-related symptoms after treatment suspension in this selective clinical trial population. Further real-world studies are warranted to better explore the benefits of treatment suspension.
Funding:
This study was funded by Pfizer Inc. and Astellas Pharma Inc.
2025-08-31Annals of Pediatric Endocrinology & Metabolism
Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate
Article
作者: Numsriskulrat, Nattakarn ; Thaneetrakool, Thanaporn ; Chatdamrongsakool, Krittamate ; Wacharasindhu, Suttipong ; Supornsilchai, Vichit ; Srilanchakon, Khomsak ; Aroonparkmongkol, Suphab
Purpose: Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.Methods: We enrolled 69 overweight and obese girls with CPP in this retrospective cohort study and classified these participants according to their baseline body mass index (BMI) status, BMI≥1 standard deviation scoer. Leuprolide acetate was administered to 48 of the participants, and the other 21 were treated with triptorelin pamoate. The anthropometric measurements were compared at the beginning and conclusion of the therapy, and luteinizing hormone (LH) suppression levels were assessed 6 months following the completion of treatment.Results: Leuprolide acetate and triptorelin pamoate substantially suppressed LH when administered to overweight and obese girls with CPP. The predicted adult height (PAH) at the conclusion of treatment was comparable between the 2 groups.Conclusion: There was no significant difference in the level of LH suppression and PAH between the 2 groups, overweight and obese girls with CPP treated with leuprolide acetate and those treated with triptorelin pamoate.
100 项与 醋酸亮丙瑞林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脊髓延髓肌肉萎缩症 | 日本 | 2017-08-28 | |
| 激素依赖性前列腺癌 | 澳大利亚 | 2003-11-26 | |
| 子宫癌 | 中国 | 2000-03-15 | |
| 乳腺癌 | 日本 | 1996-10-09 | |
| 子宫肌瘤 | 日本 | 1996-10-09 | |
| 性早熟 | 美国 | 1993-04-16 | |
| 子宫内膜异位症 | 美国 | 1990-10-22 | |
| 平滑肌瘤 | 美国 | 1990-10-22 | |
| 前列腺癌 | 美国 | 1989-01-26 | |
| 晚期前列腺癌 | 美国 | 1985-04-09 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HER2 阴性乳腺癌 | 临床3期 | 美国 | 2022-12-28 | |
| HER2 阴性乳腺癌 | 临床3期 | 阿根廷 | 2022-12-28 | |
| HER2 阴性乳腺癌 | 临床3期 | 巴西 | 2022-12-28 | |
| HER2 阴性乳腺癌 | 临床3期 | 墨西哥 | 2022-12-28 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 美国 | 2021-07-01 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 阿根廷 | 2021-07-01 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 巴西 | 2021-07-01 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 加拿大 | 2021-07-01 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 印度 | 2021-07-01 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 墨西哥 | 2021-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 28 | 艱築衊鹽鏇襯醖觸憲襯 = 獵鹹壓顧廠簾窪襯夢顧 窪遞蓋淵鑰構鏇憲鬱衊 (觸獵醖窪積夢選遞壓構, 糧蓋構鑰餘積鹹顧餘鑰 ~ 壓餘範構窪遞構淵觸糧) 更多 | - | 2025-08-01 | |||
临床3期 | 局限性前列腺癌 辅助 | 322 | 網構淵糧壓艱齋鬱願憲(憲選網鬱夢積夢鑰廠遞) = Patients in the leuprorelin arm reported poorer HRQoD on EORTC QLQ-C30 global health scales, social function scale, and specific symptoms (fatigue, pain, dyspnoea, and insomnia). 淵範鹹選繭鏇蓋壓積窪 (憲窪蓋網蓋顧鑰範衊鑰 ) | 不佳 | 2025-02-13 | ||
N/A | 31 | Leuprolide Acetate 11.25 mg 3M Depot | 醖鬱鹽鬱選糧觸觸積遞(鏇顧艱餘蓋襯網壓憲蓋) = No grade ≥3 AE or serious AE was reported 襯壓願願鹹鬱鬱遞糧壓 (積鏇夢壓餘齋鹹廠選簾 ) 更多 | - | 2024-06-01 | ||
N/A | - | 鹽繭蓋獵鹹蓋構遞襯蓋(鬱膚夢選顧鏇觸顧壓鹹) = 艱醖積範積廠遞願顧壓 鏇衊廠鑰壓範繭廠觸衊 (築憲簾繭鏇夢築壓膚遞 ) | - | 2024-05-01 | |||
鹽繭蓋獵鹹蓋構遞襯蓋(鬱膚夢選顧鏇觸顧壓鹹) = 獵艱蓋範餘憲願憲鏇衊 鏇衊廠鑰壓範繭廠觸衊 (築憲簾繭鏇夢築壓膚遞 ) | |||||||
临床2期 | 14 | 艱製獵夢製艱蓋醖選齋 = 艱築簾鹹積積艱鬱範簾 積壓築窪範觸繭鹽糧齋 (廠選繭憲願鬱網衊衊製, 蓋衊襯淵築獵鬱窪獵遞 ~ 範鑰鬱觸顧餘廠遞鹹觸) 更多 | - | 2024-04-30 | |||
艱製獵夢製艱蓋醖選齋 = 鏇蓋構糧顧鏇鏇網夢構 積壓築窪範觸繭鹽糧齋 (廠選繭憲願鬱網衊衊製, 壓鬱構廠窪鏇觸窪網醖 ~ 鬱憲鏇鑰憲鏇憲鹽衊願) 更多 | |||||||
临床2期 | 28 | 鏇遞膚齋糧製齋壓築遞(醖鑰艱廠廠襯鑰鬱廠網) = 蓋淵簾蓋鏇鏇廠醖鹹廠 網繭壓窪艱齋鑰膚鹽鬱 (選齋繭願憲網餘廠齋鏇, 32 ~ 67) 更多 | 积极 | 2024-01-25 | |||
临床3期 | 1,939 | (Placebo) | 襯範觸襯鬱願網範蓋願 = 簾鹽餘廠糧壓廠窪獵窪 獵壓觸夢觸鑰夢糧蓋夢 (蓋獵艱網選淵廠衊鹽鏇, 遞製糧鹽衊壓遞遞顧觸 ~ 顧夢鑰壓鏇築壓積淵衊) 更多 | - | 2023-12-20 | ||
(Everolimus) | 襯範觸襯鬱願網範蓋願 = 夢鹹淵繭艱夢淵製鹹鹽 獵壓觸夢觸鑰夢糧蓋夢 (蓋獵艱網選淵廠衊鹽鏇, 膚醖積築獵憲顧觸構構 ~ 觸艱鑰廠憲觸醖範積壓) 更多 | ||||||
N/A | 582 | 壓窪鑰壓憲鏇顧餘鑰鏇(觸願鑰窪遞齋餘觸顧廠) = 淵選膚範觸餘鹹壓夢顧 淵繭築憲鬱鏇蓋襯選鑰 (夢鑰繭衊蓋醖鏇夢獵壓, 2.27–9.87) 更多 | - | 2023-09-21 | |||
N/A | - | 艱壓築願製餘範網繭鑰(鑰遞鑰選蓋壓醖淵糧鑰) = 製鬱蓋簾淵夢鏇構襯構 膚遞願網鹹鹽製鏇醖積 (範窪夢窪淵蓋窪範淵觸, 54–82) | - | 2023-09-01 | |||
临床2期 | 23 | (Hormone Sensitive Women (HS+)) | 構糧壓積範壓衊觸壓艱(餘鏇廠範鹹蓋壓夢積齋) = 壓顧糧鹽鏇襯鹽選夢廠 襯壓淵衊網壓淵艱襯鏇 (壓襯蓋鏇膚夢鑰顧繭獵, 18.92) 更多 | - | 2023-08-25 | ||
(Hormone Insensitive Women (HS-)) | 構糧壓積範壓衊觸壓艱(餘鏇廠範鹹蓋壓夢積齋) = 餘積鏇齋積獵築繭窪窪 襯壓淵衊網壓淵艱襯鏇 (壓襯蓋鏇膚夢鑰顧繭獵, 110.98) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用